1-2 of 2
Christopher Walker, B.S.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Joshua J Oaks, B.S., Christopher Walker, B.S., Ramasamy Santhanam, Ph.D, Carolyn Paisie, B.S., Anna Eiring, Ph.D, Bin Zhang, Ph.D, Bastianella Perazzona, Ph.D, Y. Ma, Charlene Mao, Guido Marcucci, MD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Stefano Volinia, MD, Jorge E. Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, Ph.D, Robert Bittman, Ph.D, Ching-Shih Chen, Ph.D, Ralph B. Arlinghaus, PhD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Ravi Bhatia, MD, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 515.
https://doi.org/10.1182/blood.V116.21.515.515
Published: 2010
Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2901.
https://doi.org/10.1182/blood.V116.21.2901.2901
Published: 2010